The WSJ today penned the headline Pfizer Is Dealt Setback On HIV-Drug Approval.
In the article the WSJ wrote about the new drug maraviroc: "Pfizer Inc.'s pipeline was dealt a surprise blow last night, when the FDA delayed the approval of one of its most interesting drug prospects, a new type of medicine for HIV."
The WSJ also said that "The FDA isn't asking for any more clinical trials."
The FDA apparently couldn't be reached for comment last night.
So did the allegations related to illegal premarketing of maraviroc result in this debacle?
Make up your own mind and read all the maraviroc allegations by Pfizer's internal whistleblower here.
No comments:
Post a Comment